 |
|
Oral Contraceptives, Chlamydia trachomatis Infection, and Pelvic Inflammatory DiseaseA Word of Caution About Protection
A. Eugene Washington, MD, MSc;
Sandra Gove, MD, MPH;
Julius Schachter, PhD;
Richard L. Sweet, MD
JAMA. 1985;253(15):2246-2250.
Abstract
| |
Management of pelvic inflammatory disease (PID) and decisions about contraception are being influenced by reports that oral contraceptives decrease the risk of PID. To evaluate the validity of this association, we have examined published epidemiologic evidence and reviewed relevant information from other disciplines. Current information does not permit the generalization that oral contraceptives protect against all forms of PID. Most studies conducted (1) have been limited to hospitalized women, who represent less than 25% of all PID cases and are likely to have relatively severe forms of the disease, and (2) have failed to distinguish between gonococcal and nongonococcal PID. While oral contraceptives may provide some protection against gonococcal PID, no basis exists for assuming similar protection is provided against chlamydial PID. In fact, epidemiologic and biologic evidence suggests that infection with Chlamydia trachomatis, the leading cause of nongonococcal PID, is enhanced by oral contraceptives. We judge the conclusion that oral contraceptives protect against all PID to be premature, and urge caution in its application in health policy and clinical decisions.
(JAMA 1985;253:2246-2250)
Author Affiliations
From the Division of Sexually Transmitted Diseases, Center for Prevention Services, Centers for Disease Control, Atlanta (Dr Washington); and the Andrew W. Mellon Program in Clinical Epidemiology, Institute for Health Policy Studies (Drs Gove and Washington), and the Departments of Laboratory Medicine (Dr Schachter) and Obstetrics, Gynecology, and Reproductive Sciences (Dr Sweet), University of California School of Medicine, San Francisco.
Footnotes
Reprint requests to Technical Information Services, Center for Prevention Services, Centers for Disease Control, Atlanta, GA 30333.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Regulation of surfactant protein D in the mouse female reproductive tract in vivo
Oberley et al.
Mol Hum Reprod 2007;13:863-868.
ABSTRACT
| FULL TEXT
An update on pelvic inflammatory disease
Ross
Sex. Transm. Infect. 2002;78:18-19.
ABSTRACT
| FULL TEXT
Hormonal markers of susceptibility to sexually transmitted infections: are we taking them seriously?
Brabin
BMJ 2001;323:394-395.
FULL TEXT
Adolescents and Condom Use
Joffe
Arch Pediatr Adolesc Med 1993;147:746-754.
ABSTRACT
Effectiveness and Efficiency of Selective vs Universal Screening for Chlamydial Infection in Sexually Active Young Women
Sellors et al.
Arch Intern Med 1992;152:1837-1844.
ABSTRACT
Self-reported Pelvic Inflammatory Disease in the United States, 1988
Aral et al.
JAMA 1991;266:2570-2573.
ABSTRACT
Assessing Risk for Pelvic Inflammatory Disease and Its Sequelae
Washington et al.
JAMA 1991;266:2581-2586.
ABSTRACT
Pathogenesis of Pelvic Inflammatory Disease: What Are the Questions?
Rice and Schachter
JAMA 1991;266:2587-2593.
ABSTRACT
Decreased Risk of Symptomatic Chlamydial Pelvic Inflammatory Disease Associated With Oral Contraceptive Use
Wolner-Hanssen et al.
JAMA 1990;263:54-59.
ABSTRACT
The Relationship of Tubal Infertility to Barrier Method and Oral Contraceptive Use
Cramer et al.
JAMA 1987;257:2446-2450.
ABSTRACT
Criteria for Selective Screening for Chlamydia trachomatis Infection in Women Attending Family Planning Clinics
Handsfield et al.
JAMA 1986;255:1730-1734.
ABSTRACT
Oral Contraceptives and Chlamydia Infections
Gall
JAMA 1986;255:38-38.
ABSTRACT
Reversible Contraception for the 1980s
Grimes
JAMA 1986;255:69-75.
ABSTRACT
|
